deltatrials
Terminated PHASE1 INTERVENTIONAL 3-arm NCT04806035

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Sponsor: TG Therapeutics, Inc.

Conditions Aggressive Lymphoma CLL DLBCL Follicular Lymphoma Indolent Lymphoma MCL Marginal Zone Lymphoma Mediastinal Large B-cell Lymphoma Richter's Transformation SLL
Interventions TG-1801 Ublituximab
Updated 36 times since 2021 Last updated: Jul 29, 2024 Started: Apr 28, 2021 Primary completion: Jun 12, 2024 Completion: Jun 12, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategic/Business Decision

Other terminated trials from TG Therapeutics, Inc.

More terminations from TG Therapeutics, Inc.

Listed as NCT04806035, this PHASE1 trial focuses on Aggressive Lymphoma and CLL and remains terminated or withdrawn. Sponsored by TG Therapeutics, Inc., it has been updated 36 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

36 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Aug 2024 — Sep 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  3. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 31 earlier versions

  1. Apr 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE1

  2. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE1

  4. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE1

  5. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE1

  6. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  7. Sep 2023 — Nov 2023 [monthly]

    Recruiting PHASE1

  8. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  9. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1

  10. May 2023 — Jul 2023 [monthly]

    Recruiting PHASE1

  11. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE1

  12. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1

  13. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE1

  14. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE1

  15. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE1

  16. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1

  17. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1

  18. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  19. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  20. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1

  21. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE1

  22. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE1

  23. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1

  24. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE1

  25. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  26. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  27. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE1

  28. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  29. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  30. May 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE1

  31. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • TG Therapeutics, Inc.
Data source: TG Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations